Pancragen: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 10 sources cited

Overview

Pancragen is a bioregulator peptide (Lys-Glu-Asp-Trp) developed by the Khavinson laboratory that targets pancreatic tissue. It is designed to support normal pancreatic function, including both exocrine (digestive enzyme) and endocrine (insulin/glucagon) activity. It works at the epigenetic level to normalize gene expression in aging or damaged pancreatic cells.

Mechanism of Action

Pancragen is a tetrapeptide proposed to enter cells and interact with DNA; this is supported by molecular modeling and by changes in gene expression and promoter methylation in pancreatic cell cultures. In aging pancreatic cell cultures it raised the expression of differentiation factors for acinar cells (Pdx1, Ptf1a) and islet cells (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2), and in old rhesus monkeys it normalized insulin and C-peptide responses to glucose. Effects on glucagon or pancreatic lipase, and anti-inflammatory effects on pancreatic tissue, have not been shown in published studies. Like other Khavinson bioregulators, Pancragen works through gradual epigenetic modulation rather than immediate receptor-mediated signaling.

Pancragen Benefits: What the Research Shows

  • Khavinson and colleagues reported that 10 days of Pancragen injections normalized insulin and C-peptide responses to glucose in old female rhesus monkeys, an effect partly retained 3 weeks later
  • Studies showed the tetrapeptide Lys-Glu-Asp-Trp regulated gene expression in pancreatic cell cultures, normalizing protein synthesis patterns
  • Preclinical research showed lower blood glucose in rats with streptozotocin-induced diabetes given oral Pancragen, and faster glucose clearance in old rhesus monkeys
  • Research in Bulletin of Experimental Biology and Medicine reported lower fasting glucose, insulin and insulin resistance index in elderly patients with type 2 diabetes given Pancragen, in one small study (33 patients, with an untreated comparison group)

Pancragen Dosage

  • Oral: 10–20 mg daily in capsule form for 10–30 days
  • Repeat cycles every 3–6 months
  • Can be taken with or without food
  • For metabolic support: 20 mg daily for 20–30 days
  • For maintenance: 10 mg daily for 10 days every 4–6 months
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Pancragen Side Effects & Safety

Known Side Effects

  • No adverse effects are described in the published studies, but the one human study was small and its abstract reports no safety outcomes
  • Mild GI discomfort — infrequently reported
  • Theoretical risk of hypoglycemia if combined with insulin or sulfonylureas due to enhanced beta-cell function
  • Very limited clinical safety data

Safety Profile

Pancragen's safety has been little studied: the published work is cell culture, rats, a few rhesus monkeys and one small study in elderly patients with type 2 diabetes, all involving the group that developed it. As a naturally occurring tetrapeptide sequence, it is expected to have low toxicity. No serious adverse events have been reported, but human clinical trial data is very limited and no dedicated safety study has been published. Individuals with type 1 or type 2 diabetes should monitor blood glucose carefully if using Pancragen, as enhanced beta-cell function could alter insulin requirements. Coordination with a physician is recommended for diabetic patients.

What to Expect

Days 1–10: No immediate subjective effects. Epigenetic modulation of pancreatic gene expression is occurring at the cellular level. Days 10–30: Improved blood glucose stability may become measurable. Some users report improved digestion, particularly fat digestion, suggesting exocrine pancreatic support. Post-cycle: In old monkeys the effect on glucose handling partly remained 3 weeks after a 10-day course. How long any benefit lasts in people, and whether repeated cycles add to it, has not been studied.

Common Stacks

Storage & Handling

Store Pancragen capsules at room temperature (15–25°C) in a dry place away from direct sunlight. Shelf life is typically 2–3 years for encapsulated bioregulators. No refrigeration needed for oral form.

Pricing & Available Variants

$60price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Korkushko OV, Khavinson VKh, Shatilo VB, et al. Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011.
  2. Goncharova ND, Ivanova LG, Oganian TÉ, et al. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Adv Gerontol. 2014.
  3. Goncharova ND, Ivanova LG, Oganyan TE, et al. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys. Adv Gerontol. 2015.
  4. Khavinson VKh, Gavrisheva NA, Malinin VV, et al. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bull Exp Biol Med. 2007.
  5. Khavinson VKh, Durnova AO, Polyakova VO, et al. Effects of pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med. 2013.
  6. Khavinson VKh, Sevost'ianova NN, Durnova AO, et al. Tetrapeptide stimulates functional activity of the pancreatic cells in aging. Adv Gerontol. 2012.
  7. Ashapkin VV, Linkova NS, Khavinson VKh, et al. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015.
  8. Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012.
  9. Tarnovskaya SI, Yakutseni PP, Khavinson VKh. Study of interactions between DNA and tetrapeptides using methods of molecular mechanics. Bull Exp Biol Med. 2014.
  10. Khavinson VKh, Gapparov MM, Sharanova NE, et al. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide. Bull Exp Biol Med. 2010.

Related Peptides

Track Pancragen in Your Protocol

Log your Pancragen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free